Abstract: Described is a configuration to remove false paths from an emulation netlist in a chip design under test (DUT). The configuration identifies, in an original netlist, an original subgraph of original logic gates, a subset of inputs (TI), and a subset of outputs (TO). The configuration generates a replicated subgraph of the original subgraph, the replicated subgraph having replicated logic gates corresponding to the original logic gates. The configuration connects the TI with a first replicated logic gate to a constant propagation source and remaining inputs of the replicated logic gates with corresponding original logic gates in the original netlist. The configuration disconnects, in the original netlist, output loads of TO, and connects the output loads of TO with a corresponding equivalent TO in the replicated subgraph. The configuration deletes, in the original netlist, original logic gates unconnected with an output load for TO in the original netlist.

Abstract: Embodiments described herein relate to the efficient generation of synthetic datasets that represent many-to-many relationships. In particular, certain embodiments implement a particular factorization for many-to-many generative models, which leads to a scalable generation framework by combining random graph theory and representation learning. Further embodiments we extend the framework to establish the notion of differential privacy within the synthetically generated data. The embodiments described herein are therefore able to generate synthetic datasets efficiently while preserving information within and across many-to-many datasets with improved accuracy.

Abstract: Disclosed is a configuration to compute weakly connected components (WCCs) in a parallel, scalable and deterministic manner. The configuration receives an undirected original graph having vertices and edges. An undefined value is assigned to all the vertices of the graph. Thereafter, each vertex is visited and assigned a WCCID (index to identify a WCC). The visitation of vertices may determine whether there are one or more thread collisions. A collision is when two threads attempt to identify the same WCC. From these collisions a new graph may be generated, a collision graph, on which the same algorithm is iterated to compute WCCs of that collision graph. The process is iterated until no further collisions are determined. In a post process, the configuration merges the WCCIDs of the collision graphs to produce the WCCIDs of the original graph.

Abstract: A system identifies strongly connected components of a circuit design. The system receiving a circuit design represented as a graph including a set of vertices and a set of edges. The system marks each vertex of the set of vertices void. The system executes multiple threads, where each thread performs following steps concurrently. The thread selects a vertex from the set of vertices with void state. The thread performs a depth first search starting from the selected vertex. The thread marks a vertex as processed once the depth first search started from that vertex is completed. The depth first search skips vertices marked as processed. The thread determines a candidate SCC based on the nodes traversed by the depth first search. Once a set of candidate SCCs is determined, the system eliminates some of the candidate SCCs and stores the remaining candidate SCCs as SCCs of the graph.

Abstract: A system obtains deterministic results of netlist transformation in a multi-processor parallel computing system. The system receives a netlist. The system determines a set of components representing components with assigned identifiers. The system determines identifiers for remaining components. The system visits a component of the remaining components of the netlist in a topological order starting from the set of components. The system assigns a new identifier to the visited component. The new identifier is generated based on properties of the visited component and a connection of the visited component with at least one component of the set of components. Once the component is assigned an identifier, the system adds the component to the set of components. The system repeats these steps to assign an identifier to remaining components that are not included in the set.

Abstract: Described is a configuration to remove false paths from an emulation netlist in a chip design under test (DUT). The configuration identifies, in an original netlist, an original subgraph of original logic gates, a subset of inputs (TI), and a subset of outputs (TO). The configuration generates a replicated subgraph of the original subgraph, the replicated subgraph having replicated logic gates corresponding to the original logic gates. The configuration connects the TI with a first replicated logic gate to a constant propagation source and remaining inputs of the replicated logic gates with corresponding original logic gates in the original netlist. The configuration disconnects, in the original netlist, output loads of TO, and connects the output loads of TO with a corresponding equivalent TO in the replicated subgraph. The configuration deletes, in the original netlist, original logic gates unconnected with an output load for TO in the original netlist.

Abstract: The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as well as pharmaceutical compositions containing such compounds. The compounds are useful in treating diseases and conditions mediated by TEAD, such as cancer.

Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, Het, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein p, s, A, R3 and Re are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, Het, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, Ar, A, W, X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, W, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Abstract: Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, W, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.